Checkpoint Therapeutics, Inc. is a Waltham, Massachusetts biopharmaceutical company developing cancer medicines, including the anti-PD-L1 antibody cosibelimab and the investigational EGFR inhibitor olafertinib. Its work centers on oncology therapies designed to engage the immune response or target specific tumor mutations, with earlier-stage programs also in development. Sun Pharma completed its acquisition of Checkpoint Therapeutics on May 30, 2025.
BeyondSpringFounded in 2010, BeyondSpring is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies, centered on its investigational lead asset Plinabulin. The Florham Park company is advancing Plinabulin as a GEF-H1 agonist that promotes dendritic-cell maturation and may help re-sensitize tumors after checkpoint-inhibitor treatment while reducing chemotherapy-induced neutropenia. Its development program has treated more than 700 cancer patients and includes the confirmatory DUBLIN-4 Phase 3 program in non-small-cell lung cancer.NEW YORK, NY
STCubeSTCube is a Seoul-based biotechnology company developing precision immunotherapies for difficult-to-treat, resistant and recurrent cancers. Its central program is nelmastobart, described as the first anti-BTN1A1 immune-checkpoint inhibitor, developed through collaboration with institutions including MD Anderson Cancer Center. The company completed its first-in-human Phase 1 trial and is advancing biomarker-driven studies in colorectal and non-small-cell lung cancers.ROCKVILLE, MD
Kite PharmaKite Pharma is a cell therapy company founded in 2009 as a pioneer in cell therapy research. It researches, develops, manufactures, and commercializes cell therapies, including CAR T-cell therapies, and opened its commercial manufacturing site in El Segundo in 2016. Acquired by Gilead Sciences in 2017, Kite operates as an independent operating company within Gilead.FREDERICK, MD
Tactical TherapeuticsFounded in 2005 by cancer scientist and patent attorney Rashida A. Karmali, Tactical Therapeutics is a clinical-stage biopharmaceutical company built around her long career in cancer research, drug development, and intellectual property law. The company develops CTO, an oral therapy designed to reach the brain, for patients with glioblastoma and other cancers that have resisted treatment. Karmali has authored more than 100 scientific publications and holds eight U.S. patents alongside more than 75 international patents.NEW YORK, NY